Stock listing

Hamburg:IMR AC Immune SA Aktie

German listing (Hamburg) of AC Immune SA · home listing NASDAQ:ACIU

Follow AC Immune SA into a list and get an email when it puts out news.

Home listing price · NASDAQ:ACIU

$1.95 USD -0.15 (-7.1%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:ACIU

Past year -33.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.93 – $2.16 USDNov 20, 2026
Volume
298,383 sharesNov 20, 2026
Market cap
$193.9M USDAt the close on Nov 20, 2026 · price × 99.43M shares outstanding
52-week range
$1.93 – $3.90 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$497,312 USDMedian day 148,474 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
AC Immune SA logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ACIU · Home$1.95 USD-0.15 (-7.1%)298,383$2.16$2.16$1.93$2.10Close on Nov 20, 2026
Frankfurt:IMR€1.82 EUR+0.04 (+2.2%)—€1.856€1.856€1.82€1.78Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ACIU · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.95-0.15-7.1%$2.16$2.16$1.93298,383
$2.10-0.01-0.5%$2.16$2.16$2.07680,189
$2.11+0.02+1.0%$2.06$2.13$2.031117,134
$2.09-0.04-1.9%$2.08$2.11$2.0499,323
$2.13-0.01-0.5%$2.21$2.21$2.075114,784
$2.14-0.12-5.3%$2.21$2.23$2.12121,753
$2.26-0.03-1.3%$2.32$2.33$2.2391,386
$2.29-0.15-6.1%$2.38$2.39$2.28144,157
$2.44+0.21+9.4%$2.32$2.55$2.17469,484
$2.23+0.12+5.7%$2.10$2.25$2.095180,406
$2.11-0.18-7.9%$2.26$2.26$2.02301,977
$2.29+0.20+9.6%$2.18$2.29$2.13324,624
$2.09+0.03+1.5%$2.06$2.16$2.06134,320
$2.06-0.16-7.2%$2.23$2.32$2.015470,827
$2.22-0.15-6.3%$2.37$2.37$2.21105,104
$2.370.000.0%$2.34$2.43$2.32105,208
$2.37+0.12+5.3%$2.21$2.39$2.19227,120
$2.25-0.06-2.6%$2.31$2.36$2.03469,024
$2.31-0.11-4.5%$2.41$2.42$2.29397,919
$2.42-0.08-3.2%$2.46$2.48$2.40139,548
$2.50+0.03+1.2%$2.45$2.52$2.4573,027
$2.47-0.02-0.8%$2.46$2.52$2.4689,033
$2.49+0.055+2.3%$2.41$2.525$2.395140,103
$2.435+0.045+1.9%$2.38$2.44$2.3788,823
$2.39-0.06-2.4%$2.45$2.47$2.38126,849
$2.45+0.05+2.1%$2.43$2.46$2.38186,886
$2.400.000.0%$2.37$2.41$2.35209,775
$2.40-0.05-2.0%$2.43$2.44$2.39194,919
$2.45-0.05-2.0%$2.50$2.50$2.42148,474
$2.50-0.05-2.0%$2.55$2.59$2.475271,325
$2.55-0.02-0.8%$2.57$2.61$2.50231,857
$2.57+0.05+2.0%$2.52$2.59$2.50125,080
$2.52-0.19-7.0%$2.72$2.72$2.51277,841
$2.71-0.015-0.6%$2.68$2.745$2.65221,399
$2.725-0.085-3.0%$2.84$2.88$2.69320,257
$2.81+0.19+7.3%$2.64$2.835$2.57352,697
$2.62+0.02+0.8%$2.63$2.745$2.61199,646
$2.60-0.01-0.4%$2.65$2.66$2.56139,228
$2.61+0.09+3.6%$2.52$2.62$2.405189,115
$2.52-0.14-5.3%$2.66$2.66$2.452323,580
$2.66-0.17-6.0%$2.85$2.85$2.66265,287
$2.83+0.10+3.7%$2.90$2.907$2.669492,823
$2.73+0.075+2.8%$2.69$2.75$2.6678,091
$2.655+0.025+1.0%$2.63$2.72$2.57109,425
$2.63-0.05-1.9%$2.69$2.806$2.62568,461
$2.68+0.03+1.1%$2.71$2.74$2.6693,347
$2.65-0.03-1.1%$2.68$2.73$2.61124,399
$2.68+0.02+0.8%$2.65$2.70$2.5993,530
$2.66-0.10-3.6%$2.69$2.75$2.66111,832
$2.76+0.07+2.6%$2.70$2.775$2.68105,369
$2.69-0.07-2.5%$2.74$2.77$2.68157,532
$2.76-0.02-0.7%$2.78$2.81$2.725146,572
$2.78-0.08-2.8%$2.82$2.85$2.77100,865
$2.86-0.07-2.4%$2.91$2.94$2.82155,628
$2.93+0.09+3.2%$2.85$3.00$2.85171,765
$2.84+0.16+6.0%$2.70$2.865$2.70257,176
$2.68+0.04+1.5%$2.62$2.68$2.58103,465
$2.64-0.01-0.4%$2.67$2.735$2.61132,959
$2.65-0.06-2.2%$2.73$2.77$2.65105,711
$2.71-0.14-4.9%$2.83$2.91$2.685169,433
$2.85-0.07-2.4%$2.94$2.98$2.77269,061
$2.92+0.06+2.1%$2.85$2.965$2.85241,303
$2.86-0.04-1.4%$2.91$3.00$2.799371,172
$2.90+0.26+9.8%$2.66$2.945$2.65442,012
$2.64+0.06+2.3%$2.60$2.65$2.435237,111
Ticker
Hamburg:IMR
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Hamburg
Currency
EUR

What changed lately

Latest news

All AC Immune SA news

AC Immune SA on 6ix

Sector
Health care
Industry
Biotechnology
News releases
16 in the last 12 months · 124 in all · newest Nov 11, 2026 · oldest 2019
Decks
27 decks · latest October 2026

Where AC Immune SA is listed

ListingExchangeCountryCurrency
NASDAQ:ACIU · Home listingNASDAQUnited StatesUSD
gettex:IMRgettexGermanyEUR
LS Exchange:A2AR5FLS ExchangeGermanyEUR
Lang & Schwarz:A2AR5FLang & SchwarzGermanyEUR
Frankfurt:IMRFrankfurtGermanyEUR
BOATS:ACIUBOATSUnited StatesUSD
Tradegate:IMRTradegateGermanyEUR
Dusseldorf:IMRDusseldorfGermanyEUR
Hamburg:IMR · This pageHamburgGermanyEUR
Munich:IMRMunichGermanyEUR
Stuttgart:IMRStuttgartGermanyEUR
Hanover:IMRHanoverGermanyEUR
Xetra:IMRXetraGermanyEUR

Valuation

EV/sales 4.7× against a median of 14.0×: 2nd lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$110.5M USD
P/E
Loss
EV/sales
4.7×
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
6.0×
Gross margin
100.0%
Operating margin
−190.8%
Net margin
−181.9%
Debt to equity
0.1×
Beta vs S&P 500
1.56

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
AC Immune SA · NASDAQ:ACIUUS$193.9MUS$110.5Mn/a4.7×n/a6.0×−181.9%0.1×1.56
Cabaletta Bio, Inc. · NASDAQ:CABAUS$201.9M−US$97.45Mn/an/an/a0.7×n/a0.0×1.89
Bright Minds Biosciences Inc. · CSE:DRUGUS$199.5M−US$15.18Mn/an/an/a0.9×n/a0.0×0.32
Newron Pharmaceuticals S.p.A. · SIX:NWRNUS$199.5MUS$206.2Mn/a9.8×n/an/a−69.2%n/an/a
NervGen Pharma Corp. · NASDAQ:NGENUS$198.4MUS$137.8Mn/an/an/a16.4×n/a0.0×1.46
BioAge Labs, Inc. · NASDAQ:BIOAUS$196.4M−US$87.20Mn/a−10.1×n/a0.6×n/a0.0×2.06
Lineage Cell Therapeutics, Inc. · AMEX:LCTXUS$195.3MUS$152.1M111×14.0×n/a2.9×16.2%0.0×1.33
AN2 Therapeutics, Inc. · NASDAQ:ANTXUS$192.8MUS$128.4Mn/an/an/a2.5×n/a0.0×0.54
SillaJen, Inc. · KRX:215600US$192.3MUS$140.8Mn/a17.6×n/a2.6×−223.8%0.0×n/a
Cartesian Therapeutics, Inc. · NASDAQ:RNACUS$187.3MUS$114.5Mn/a112×n/an/an/an/a1.23
Artiva Biotherapeutics, Inc. · NASDAQ:ARTVUS$186.9M−US$123.1Mn/an/an/a0.6×n/a0.0×1.34
Median of the othersUS$195.8MUS$121.4M111×14.0×1.7×−69.2%0.0×1.34

Forecasts

4 strong buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
8.33 USD · Analysts' mean
EPS, year to Dec 2026
-0.34 · 2 analysts
Revenue, year to Dec 2026
22M · 3 analysts

Team and board

Officers

OfficerRole
Gary WaandersSVP, Investor Relations & Corporate Communications

Board

DirectorRole
Monika BütlerChairperson
Renée Aguiar-LucanderMember
Roy TwymanMember
Thomas GraneyMember

Events

Next results
Mar 11, 2027 (expected)
QuarterResultsShare move
Q3 2026Nov 4, 2026 · Before open+9.6%
Q2 2026Aug 5, 2026 · Before open+0.9%
Q1 2026Apr 30, 2026 · Before open+3.4%
Q4 2025Mar 12, 2026−1.5%
Q3 2025Nov 4, 2025 · Before open+3.8%
Q2 2025Aug 5, 2025 · Before open+11.6%
Q1 2025Apr 30, 2025 · Before open+1.8%
Q4 2024Mar 12, 2025 · Before open+3.1%
Q3 2024Nov 5, 2024 · Before open+10.2%
Q2 2024Aug 6, 2024 · Before open+1.1%
All 20 quarters
QuarterResultsShare move
Q1 2024May 13, 2024 · Before open+42.9%
Q4 2023Mar 14, 2024 · Before open−10.0%
Q3 2023Nov 3, 2023 · Before open−3.9%
Q2 2023Aug 4, 2023 · Before open+3.1%
Q1 2023Apr 28, 2023 · Before open+3.2%
Q4 2022Mar 16, 2023 · Before open+0.4%
Q3 2022Oct 28, 2022 · Before open−6.6%
Q2 2022Jul 28, 2022 · Before open+4.4%
Q1 2022Apr 28, 2022 · Before open−0.9%
Q4 2021Mar 22, 2022 · Before open−0.5%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (October 2026)Investor deck18 slidesOctober 2026
Investor Presentation (October 2026)Investor deck27 slidesOctober 2026
Shareholder Meeting (June 2026)Shareholder meeting43 slidesJun 11, 2026
Shareholder Meeting (June 2025)Shareholder meeting47 slidesJun 20, 2025
Shareholder Meeting (June 2024)Shareholder meeting39 slidesJun 20, 2024
Investor Presentation (May 2024)Investor deck11 slidesMay 2024
AD/PD 2024Conference12 slidesMar 9, 2024
AD/PD 2024Conference13 slidesMar 6, 2024
ADPD 2024Conference11 slidesMarch 2024
AAIC 2023Conference16 slidesJul 18, 2023
All 27 decks
DeckKindSlidesDate
Shareholder Meeting (June 2023)Shareholder meeting49 slidesJun 26, 2023
AAIC 2022Conference13 slidesAug 2, 2022
Shareholder Meeting (June 2022)Shareholder meeting50 slidesJun 24, 2022
AD/PD 2022Conference12 slidesMar 18, 2022
CTAD 2021 (Clinical Trials on Alzheimer's Disease), BostonConference15 slidesNovember 2021
Shareholder Meeting (June 2021)Shareholder meeting37 slidesJun 25, 2021
Shareholder Meeting (June 2020)Shareholder meeting34 slidesJun 26, 2020
Investor Presentation (November 2019)Investor deck26 slidesNov 6, 2019
Technical Presentation (November 2019)Technical32 slidesNov 6, 2019
KOL Breakfast NYC July 2019Conference25 slidesJul 11, 2019
Shareholder Meeting (June 2019)Shareholder meeting53 slidesJun 28, 2019
CTAD 2018 late breaking sessionConference18 slidesOct 26, 2018
Shareholder Meeting (July 2018)Shareholder meeting53 slidesJul 6, 2018
Shareholder Meeting (April 2018)Shareholder meeting26 slidesApr 27, 2018
Shareholder Meeting (June 2017)Shareholder meeting47 slidesJun 28, 2017
Technical Presentation (December 2016)Technical10 slidesDec 16, 2016
Shareholder Meeting (November 2016)Shareholder meeting16 slidesNov 15, 2016

Open Decks

IPO

Priced at US$11.00 a share on Sep 22, 2016.

Price
US$11.00 a share
Shares offered
6,000,000 common shares
Offering size
US$66 million
Underwriters' option
Up to 900,000 more shares
Underwriters
Credit Suisse, Jefferies, Leerink Partners · In the order on the cover
Shares delivered
On or about Sep 28, 2016

Steps

StepWhen
Draft sent to the SEC in confidenceAug 28, 2015
Filed publiclyMay 31, 2016
Amended 7 timesNewest Sep 22, 2016
Declared effective by the SECSep 22, 2016
Shares registered with an exchangeSep 23, 2016
Final prospectus, with the priceSep 23, 2016

Filings

FilingFiled
424B4 · ProspectusSep 23, 2016
CERTNAS · Nasdaq's certificate of listingSep 23, 2016
8-A12B · Registration of shares for listing on an exchangeSep 23, 2016
EFFECT · Notice that a registration is effectiveSep 22, 2016
F-1/A · Registration statement, amendedSep 22, 2016
FWP · Free writing prospectusSep 21, 2016
F-1/A · Registration statement, amendedSep 21, 2016
CORRESP · Letter to the SECSep 20, 2016
CORRESP · Letter to the SECSep 20, 2016
CORRESP · Letter to the SECSep 20, 2016
All 40 filings
FilingFiled
FWP · Free writing prospectusSep 16, 2016
CORRESP · Letter to the SECSep 16, 2016
F-1/A · Registration statement, amendedSep 16, 2016
UPLOAD · Letter from the SECSep 15, 2016
CORRESP · Letter to the SECSep 13, 2016
F-1/A · Registration statement, amendedSep 13, 2016
UPLOAD · Letter from the SECSep 9, 2016
F-1/A · Registration statement, amendedSep 7, 2016
CORRESP · Letter to the SECJul 11, 2016
F-1/A · Registration statement, amendedJul 11, 2016
UPLOAD · Letter from the SECJun 16, 2016
CORRESP · Letter to the SECJun 15, 2016
F-1/A · Registration statement, amendedJun 15, 2016
UPLOAD · Letter from the SECJun 14, 2016
CORRESP · Letter to the SECJun 8, 2016
CORRESP · Letter to the SECMay 31, 2016
F-1 · Registration statementMay 31, 2016
UPLOAD · Letter from the SECMay 25, 2016
DRSLTR · Letter to the SEC with a draftApr 29, 2016
DRS/A · Draft registration statement, amendedApr 29, 2016
UPLOAD · Letter from the SECDec 3, 2015
DRS/A · Draft registration statement, amendedNov 24, 2015
DRSLTR · Letter to the SEC with a draftOct 23, 2015
DRS/A · Draft registration statement, amendedOct 23, 2015
UPLOAD · Letter from the SECOct 19, 2015
DRSLTR · Letter to the SEC with a draftOct 2, 2015
DRS/A · Draft registration statement, amendedOct 2, 2015
DRS/A · Draft registration statement, amendedSep 25, 2015
UPLOAD · Letter from the SECSep 24, 2015
DRS · Draft registration statementAug 28, 2015

Open IPO · From the cover of the final prospectus (424B4) filed Sep 23, 2016

Financials

Annual, in CHF

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue3.57M27.3M14.8M3.94M015.4M110.5M6.91M20.3M23.2M
Cost of revenue62.6M54.6M60.3M62.3M59.5M50.4M44.3M32.7M25.8M
Gross profit3.57M-35.3M-39.8M3.94M-62.3M-44.1M60.0M-37.1M-12.4M-2.56M
Research and development56.4M62.6M54.6M60.3M62.3M59.5M50.4M44.3M32.7M25.8M
Selling, general and administrative11.7M11.4M10.6M9.58M17.9M18.6M16.1M12.5M10.1M7.90M
Operating income-69.3M-52.4M-53.6M-70.8M-79.0M-61.3M44.5M-49.5M-22.5M-10.5M
Depreciation and amortization1.39M1.49M1.67M1.79M1.90M1.53M1.27M961.0K580.0K278.0K
EBITDA-67.9M-50.9M-52.0M-69.1M-77.1M-59.7M45.8M-48.6M-22.0M-10.2M
Interest expense191.0K133.0K176.0K355.0K581.0K184.0K1.89M298.0K147.0K7.00K
Income before tax-70.4M-50.9M-54.2M-70.7M-73.0M-61.9M45.4M-51.0M-26.4M-7.10M
Income tax03.00K10.0K13.0K3.00K00000
Net income-70.4M-50.9M-54.2M-70.8M-73.0M-61.9M45.4M-51.0M-26.4M-7.10M
Earnings per share, basic-0.70-0.51-0.64-0.85-0.97-0.860.64-0.82-0.46-0.14
Earnings per share, diluted-0.70-0.51-0.64-0.85-0.97-0.860.64-0.82-0.46-0.14

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents26.8M36.3M78.5M31.6M82.2M160.9M193.6M156.5M124.4M152.2M
Short-term investments64.7M129.2M24.6M91.0M116.0M65.0M95.0M30.0M00
Receivables1.34M014.8M408.0K975.0K1.59M1.40M4.10M3.72M1.41M
Inventory-622.0K1-1.40M-1.92M-1.40M0-1.36M389.0K
Current assets96.7M172.0M125.2M128.1M202.6M231.8M292.8M192.9M129.5M154.9M
Property, plant and equipment1.99M2.65M3.38M4.26M5.12M4.42M3.92M3.32M2.35M1.12M
Goodwill0000
Total assets154.3M230.9M182.8M185.9M261.4M238.7M299.3M196.6M132.0M156.1M
Accounts payable2.07M2.66M1.68M929.0K2.00M2.18M142.0K1.98M1.09M4.04M
Current liabilities94.7M100.8M13.6M11.5M20.0M14.0M17.5M13.1M9.75M9.92M
Long-term debt0186.0K395.0K0
Total debt4.55M5.43M3.50M2.80M2.91M2.22M2.91M551.8K498.4K0
Total liabilities109.4M118.6M22.2M16.9M29.5M23.3M26.8M18.9M15.2M13.7M
Shareholders' equity44.9M112.3M160.6M169.0M232.0M215.5M272.4M177.6M116.8M142.4M
Shares outstanding100.8M99.7M84.7M83.6M75.0M71.9M71.1M61.8M57.4M50.1M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-69.3M65.8M-60.4M-73.6M-65.7M-59.5M55.2M-44.1M-22.1M-5.65M
Capital spending-900.0K-576.0K-801.0K-1.24M-2.63M-1.71M-1.89M-1.86M-1.80M-899.0K
Free cash flow-70.2M65.3M-61.2M-74.8M-68.3M-61.2M53.3M-45.9M-23.9M-6.54M
Cash from investing63.5M-105.3M65.6M23.8M-53.7M28.3M-66.9M-32.0M-1.84M-899.0K
Cash from financing-1.02M-1.12M43.3M-1.35M40.7M-803.0K49.6M109.4M271.0K78.8M
Dividends paid-7.00K0000
Share buybacks00-100.0K0071.0K82.9M
Change in cash-6.74M-40.6M48.5M-51.2M-78.6M-32.0M38.0M33.3M-23.7M72.2M

Open Financials

Filings

FilingDateTypeFiled with
6-K · Report of a foreign issuerNov 4, 2026Current reportSEC
3/A · Initial statement of ownership, amendedOct 9, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 9, 2026Insider tradeSEC
6-K · Report of a foreign issuerOct 2, 2026Current reportSEC
6-K · Report of a foreign issuerSep 23, 2026Current reportSEC
6-K · Report of a foreign issuerSep 3, 2026Current reportSEC
6-K · Report of a foreign issuerAug 20, 2026Current reportSEC
6-K · Report of a foreign issuerAug 11, 2026Current reportSEC
6-K · Report of a foreign issuerAug 5, 2026Current reportSEC
6-K · Report of a foreign issuerJun 30, 2026Current reportSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
6-K · Report of a foreign issuerJun 11, 2026Current reportSEC
6-K · Report of a foreign issuerJun 11, 2026Current reportSEC
4 · Change in ownershipMay 18, 2026Insider tradeSEC
144 · Notice of proposed saleMay 15, 2026Other filingsSEC
6-K · Report of a foreign issuerMay 15, 2026Current reportSEC
6-K · Report of a foreign issuerMay 12, 2026Current reportSEC
6-K · Report of a foreign issuerApr 30, 2026Current reportSEC
6-K · Report of a foreign issuerApr 30, 2026Current reportSEC
4/A · Change in ownership, amendedApr 16, 2026Insider tradeSEC
4 · Change in ownershipApr 16, 2026Insider tradeSEC
144 · Notice of proposed saleApr 15, 2026Other filingsSEC
6-K · Report of a foreign issuerApr 7, 2026Current reportSEC
3 · Initial statement of ownershipApr 1, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 20, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
6-K · Report of a foreign issuerMar 13, 2026Current reportSEC
20-F · Annual reportMar 13, 2026Annual reportSEC
6-K · Report of a foreign issuerFeb 24, 2026Current reportSEC
6-K · Report of a foreign issuerFeb 17, 2026Current reportSEC
144 · Notice of proposed saleJan 15, 2026Other filingsSEC
6-K · Report of a foreign issuerDec 11, 2025Current reportSEC
6-K · Report of a foreign issuerNov 4, 2025Current reportSEC
144 · Notice of proposed saleOct 3, 2025Other filingsSEC
144 · Notice of proposed saleSep 12, 2025Other filingsSEC
6-K · Report of a foreign issuerSep 4, 2025Current reportSEC
6-K · Report of a foreign issuerAug 5, 2025Current reportSEC
144 · Notice of proposed saleJul 24, 2025Other filingsSEC
6-K · Report of a foreign issuerJun 20, 2025Current reportSEC
6-K · Report of a foreign issuerJun 11, 2025Current reportSEC
6-K · Report of a foreign issuerMay 19, 2025Current reportSEC
6-K · Report of a foreign issuerApr 30, 2025Current reportSEC
6-K · Report of a foreign issuerMar 13, 2025Current reportSEC
20-F · Annual reportMar 13, 2025Annual reportSEC
6-K · Report of a foreign issuerDec 18, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedDec 13, 2024Big-stake noticeSEC
6-K · Report of a foreign issuerDec 10, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
6-K · Report of a foreign issuerNov 14, 2024Current reportSEC
6-K · Report of a foreign issuerNov 5, 2024Current reportSEC
144 · Notice of proposed saleSep 27, 2024Other filingsSEC
6-K · Report of a foreign issuerSep 19, 2024Current reportSEC
144 · Notice of proposed saleSep 18, 2024Other filingsSEC
6-K · Report of a foreign issuerSep 17, 2024Current reportSEC
6-K · Report of a foreign issuerAug 28, 2024Current reportSEC
424B5 · ProspectusAug 6, 2024Offer documentSEC
6-K · Report of a foreign issuerAug 6, 2024Current reportSEC
6-K · Report of a foreign issuerAug 6, 2024Current reportSEC
EFFECT · Notice that a registration is effectiveAug 1, 2024Other filingsSEC
6-K · Report of a foreign issuerJul 31, 2024Current reportSEC
CORRESP · Letter to the SECJul 29, 2024Other filingsSEC
F-3/A · Registration statement, amendedJul 26, 2024Offer documentSEC
6-K · Report of a foreign issuerJul 25, 2024Current reportSEC
6-K · Report of a foreign issuerJun 20, 2024Current reportSEC
6-K · Report of a foreign issuerMay 21, 2024Current reportSEC
144 · Notice of proposed saleMay 16, 2024Other filingsSEC
6-K · Report of a foreign issuerMay 13, 2024Current reportSEC
6-K · Report of a foreign issuerMay 13, 2024Current reportSEC
UPLOAD · Letter from the SECMar 19, 2024Other filingsSEC
F-3 · Registration statementMar 14, 2024Offer documentSEC
6-K · Report of a foreign issuerMar 14, 2024Current reportSEC
20-F · Annual reportMar 14, 2024Annual reportSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2024Big-stake noticeSEC
6-K · Report of a foreign issuerJan 22, 2024Current reportSEC
6-K · Report of a foreign issuerJan 3, 2024Current reportSEC
144 · Notice of proposed saleDec 28, 2023Other filingsSEC
SC 13G/A · Big-stake notice, amendedDec 19, 2023Big-stake noticeSEC
6-K · Report of a foreign issuerDec 19, 2023Current reportSEC
424B5 · ProspectusDec 15, 2023Offer documentSEC
144 · Notice of proposed saleDec 15, 2023Other filingsSEC
6-K · Report of a foreign issuerDec 15, 2023Current reportSEC
144 · Notice of proposed saleDec 11, 2023Other filingsSEC
144 · Notice of proposed saleDec 6, 2023Other filingsSEC
6-K · Report of a foreign issuerDec 1, 2023Current reportSEC
6-K · Report of a foreign issuerNov 3, 2023Current reportSEC
144 · Notice of proposed saleAug 22, 2023Other filingsSEC
144 · Notice of proposed saleAug 21, 2023Other filingsSEC
144 · Notice of proposed saleAug 17, 2023Other filingsSEC
144 · Notice of proposed saleAug 9, 2023Other filingsSEC
144 · Notice of proposed saleAug 8, 2023Other filingsSEC
6-K · Report of a foreign issuerAug 4, 2023Current reportSEC
6-K · Report of a foreign issuerJul 26, 2023Current reportSEC
144 · Notice of proposed saleJul 24, 2023Other filingsSEC
144 · Notice of proposed saleJul 21, 2023Other filingsSEC
144 · Notice of proposed saleJul 18, 2023Other filingsSEC
144 · Notice of proposed saleJul 13, 2023Other filingsSEC
144 · Notice of proposed saleJul 12, 2023Other filingsSEC
144 · Notice of proposed saleJul 10, 2023Other filingsSEC
144 · Notice of proposed saleJul 7, 2023Other filingsSEC
144 · Notice of proposed saleJul 3, 2023Other filingsSEC
144 · Notice of proposed saleJun 30, 2023Other filingsSEC
144 · Notice of proposed saleJun 30, 2023Other filingsSEC
6-K · Report of a foreign issuerJun 27, 2023Current reportSEC
6-K · Report of a foreign issuerJun 26, 2023Current reportSEC
6-K · Report of a foreign issuerMay 24, 2023Current reportSEC
6-K · Report of a foreign issuerApr 28, 2023Current reportSEC
6-K · Report of a foreign issuerMar 16, 2023Current reportSEC
20-F · Annual reportMar 16, 2023Annual reportSEC
6-K · Report of a foreign issuerMar 10, 2023Current reportSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2023Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 13, 2023Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 10, 2023Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedJan 27, 2023Big-stake noticeSEC
6-K · Report of a foreign issuerJan 26, 2023Current reportSEC
6-K · Report of a foreign issuerNov 30, 2022Current reportSEC
6-K · Report of a foreign issuerOct 28, 2022Current reportSEC
6-K · Report of a foreign issuerSep 26, 2022Current reportSEC
6-K · Report of a foreign issuerAug 2, 2022Current reportSEC
6-K · Report of a foreign issuerJul 28, 2022Current reportSEC
6-K · Report of a foreign issuerJun 24, 2022Current reportSEC
6-K · Report of a foreign issuerJun 16, 2022Current reportSEC
6-K · Report of a foreign issuerMay 25, 2022Current reportSEC
424B5 · ProspectusMay 19, 2022Offer documentSEC
6-K · Report of a foreign issuerApr 28, 2022Current reportSEC
6-K · Report of a foreign issuerApr 8, 2022Current reportSEC
6-K · Report of a foreign issuerMar 22, 2022Current reportSEC
20-F · Annual reportMar 22, 2022Annual reportSEC
6-K · Report of a foreign issuerMar 16, 2022Current reportSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2022Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2022Big-stake noticeSEC
6-K · Report of a foreign issuerNov 12, 2021Current reportSEC
6-K · Report of a foreign issuerNov 8, 2021Current reportSEC
6-K · Report of a foreign issuerOct 29, 2021Current reportSEC
6-K · Report of a foreign issuerOct 15, 2021Current reportSEC
6-K · Report of a foreign issuerOct 7, 2021Current reportSEC
6-K · Report of a foreign issuerAug 31, 2021Current reportSEC
SC 13G · Big-stake noticeAug 5, 2021Big-stake noticeSEC
6-K · Report of a foreign issuerAug 4, 2021Current reportSEC
6-K · Report of a foreign issuerJul 27, 2021Current reportSEC
6-K · Report of a foreign issuerJun 25, 2021Current reportSEC
6-K · Report of a foreign issuerMay 21, 2021Current reportSEC
EFFECT · Notice that a registration is effectiveMay 6, 2021Other filingsSEC
6-K · Report of a foreign issuerMay 5, 2021Current reportSEC
424B5 · ProspectusMay 5, 2021Offer documentSEC
CORRESP · Letter to the SECMay 3, 2021Other filingsSEC
UPLOAD · Letter from the SECApr 30, 2021Other filingsSEC
F-3 · Registration statementApr 28, 2021Offer documentSEC
6-K · Report of a foreign issuerApr 28, 2021Current reportSEC
6-K · Report of a foreign issuerMar 31, 2021Current reportSEC
6-K · Report of a foreign issuerMar 23, 2021Current reportSEC
20-F · Annual reportMar 23, 2021Annual reportSEC
6-K · Report of a foreign issuerFeb 26, 2021Current reportSEC
SC 13G · Big-stake noticeFeb 12, 2021Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 12, 2021Big-stake noticeSEC
6-K · Report of a foreign issuerFeb 11, 2021Current reportSEC
SC 13G · Big-stake noticeJan 22, 2021Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedJan 14, 2021Big-stake noticeSEC
6-K/A · Report of a foreign issuer, amendedNov 23, 2020Current reportSEC
6-K · Report of a foreign issuerNov 20, 2020Current reportSEC
6-K · Report of a foreign issuerNov 18, 2020Current reportSEC
6-K · Report of a foreign issuerNov 13, 2020Current reportSEC
EFFECT · Notice that a registration is effectiveNov 6, 2020Other filingsSEC
CORRESP · Letter to the SECNov 3, 2020Other filingsSEC
UPLOAD · Letter from the SECOct 29, 2020Other filingsSEC
F-3 · Registration statementOct 23, 2020Offer documentSEC
6-K · Report of a foreign issuerOct 21, 2020Current reportSEC
6-K · Report of a foreign issuerSep 23, 2020Current reportSEC
6-K · Report of a foreign issuerSep 8, 2020Current reportSEC
424B5 · ProspectusSep 8, 2020Offer documentSEC
6-K · Report of a foreign issuerAug 5, 2020Current reportSEC
6-K · Report of a foreign issuerJul 16, 2020Current reportSEC
6-K · Report of a foreign issuerJun 26, 2020Current reportSEC
6-K · Report of a foreign issuerMay 22, 2020Current reportSEC
6-K · Report of a foreign issuerMay 4, 2020Current reportSEC
6-K · Report of a foreign issuerApr 2, 2020Current reportSEC
6-K · Report of a foreign issuerMar 30, 2020Current reportSEC
20-F · Annual reportMar 30, 2020Annual reportSEC
6-K · Report of a foreign issuerMar 23, 2020Current reportSEC
UPLOAD · Letter from the SECFeb 25, 2020Other filingsSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2020Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 7, 2020Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 6, 2020Big-stake noticeSEC
CORRESP · Letter to the SECJan 17, 2020Other filingsSEC
UPLOAD · Letter from the SECJan 6, 2020Other filingsSEC
CORRESP · Letter to the SECDec 20, 2019Other filingsSEC
UPLOAD · Letter from the SECDec 4, 2019Other filingsSEC
6-K · Report of a foreign issuerNov 13, 2019Current reportSEC
6-K · Report of a foreign issuerNov 6, 2019Current reportSEC
6-K · Report of a foreign issuerSep 20, 2019Current reportSEC
SC 13G/A · Big-stake notice, amendedSep 16, 2019Big-stake noticeSEC
6-K · Report of a foreign issuerAug 14, 2019Current reportSEC

This page holds 200 of 313 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from AC Immune SA’s releases

Common shares
99,426,932
Fully diluted
99,426,932

Fully diluted

LineShares
Common shares99,426,932

Share count over time

CountShares
Nov 22, 202699,426,932

Open Cap table

Shareholders

Funds

HolderSharesValueAs of
iShares Biotechnology ETF433KUS$1.03MJun 30, 2026
Dimensional U.S. Small Cap ETF80,741US$177KJul 31, 2026
Fidelity Nasdaq Composite Index Fund63,601US$169KMay 31, 2026
U.S. Small Cap Portfolio45,388US$99,400Jul 31, 2026
U.S. Micro Cap Portfolio44,072US$96,518Jul 31, 2026
U.S. Vector Equity Portfolio15,821US$34,648Jul 31, 2026
JNL/DFA U.S. Small Cap Fund7,966US$18,959Jun 30, 2026
Dimensional U.S. Core Equity 2 ETF7,863US$17,220Jul 31, 2026
Dimensional US Core Equity 1 ETF5,748US$12,588Jul 31, 2026
Invesco Nasdaq Biotechnology ETF5,312US$14,130May 31, 2026
All 15 holders
HolderSharesValueAs of
AST Small-Cap Equity Portfolio4,330US$10,305Jun 30, 2026
iShares Neuroscience and Healthcare ETF3,783US$8,285Jul 31, 2026
ProShares Ultra Nasdaq Biotechnology3,721US$9,898May 31, 2026
Dimensional US Sustainability Core 1 ETF2,823US$6,182Jul 31, 2026
Blackstone Alternative Multi-Strategy Fund98US$233Jun 30, 2026

Insider trades

TradeTradeSharesPriceValueDate
Pfeifer Andrea
Director, Officer: Chief Executive Officer
Sale10,000USD 2.79US$27,900May 15, 2026
Pfeifer Andrea
Director, Officer: Chief Executive Officer
Buy10,000USD 3.14US$31,400Apr 15, 2026
Pfeifer Andrea
Director, Officer: Chief Executive Officer
Sale10,000USD 3.14US$31,400Apr 15, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Renée Aguiar-Lucander
Other companies: Egalet Corporation (Director · Feb 5, 2014 – Feb 11, 2014 · Past)
Member · Since at least Mar 18, 2026
Andrea PfeiferChief Executive Officer, Director · Since at least Mar 18, 2026
Carl Howard JuneDirector · Since at least Mar 18, 2026
Christopher James RobertsChief Financial Officer · Since at least Mar 18, 2026
Gary WaandersSVP, Investor Relations & Corporate Communications · Since at least Nov 4, 2026
Martin ZuegelInterim CEO, Director · Since at least Mar 18, 2026
Monika BuetlerDirector · Since at least Mar 18, 2026
Monika BütlerChairperson · Since at least Nov 5, 2026
Piergiorgio DonatiChief Operating Officer · Since at least Mar 20, 2026
Roy TwymanMember · Since at least Mar 18, 2026
All 11 people
PersonSeat
Thomas GraneyMember · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about AC Immune SA.